查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
循环肿瘤细胞 (Ctc) 市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)
市场调查报告书
商品编码
1190306

循环肿瘤细胞 (Ctc) 市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Circulating Tumor Cells (Ctc) Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 112 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

循环肿瘤细胞 (CTC) 市场预计在预测期内 (2022-2027) 的复合年增长率为 9.5%。

COVID-19 大流行影响了世界各地的医疗保健系统，扰乱了许多医疗机构的正常护理，并使易受伤害的癌症患者面临巨大风险。 例如，“COVID-19 大流行对癌症治疗的影响：一项全球合作研究”，2020 年 9 月，4 月 21 日至 5 月 8 日期间，共有来自 6 大洲 54 个国家/地区的 356 个中心参与。据报导， 这些设施每年为 716,979 名新癌症患者提供服务。 大多数 (88.2%) 报告在大流行期间面临提供护理的挑战。 作为先发製人战略的一部分，55.34% 缩减了服务，但其他常见原因包括系统超载 (19.94%)、缺乏个人防护设备 (19.10%)、人员短缺 (17.98%)、药物获取限制 (9.83%)。 因此，这表明 COVID-19 在化疗和放疗服务减少以及正在进行的研发研究方面扰乱了癌症治疗，从而影响了市场的增长。

此外，2021 年 9 月发表的一项研究“COVID-19 锁定与新诊断转移性结直肠癌患者的肿瘤负担相关”通过循环肿瘤 DNA 确定了 COVID-19 锁定的新诊断。他们评估了对癌症病例的影响，并报告说，锁定后诊断出的患者的肿瘤负担明显高于锁定前诊断出的患者。 这项研究表明，在 COVID-19 实施期间，肿瘤负担显着增加，对市场增长产生了巨大影响。

推动循环肿瘤细胞 (CTC) 市场增长的主要因素是生物医学成像和生物工程技术的进步、对预防医学和伴随诊断的需求增加以及癌症患病率的增加。

随着全球癌症负担的增加，必鬚根据地区和国家优先事项调整癌症治疗。 例如，根据世界卫生组织 (WHO) 于 2021 年 9 月发布的最新消息，到 2020 年，癌症将导致全球约 1000 万人死亡。 2020年，最常见的癌症（按新发病率计算）是乳腺癌（226万例）、肺癌（221万例）、结直肠癌（193万例）、前列腺癌（141万例）、皮肤（非黑色素瘤）（120万例）和胃（109 万例）。

此外，根据 Globocan 2020 年的统计数据，2020 年有 19,292,789 人被诊断出患有癌症。 在上述同一份材料中，预计2040年癌症患者人数将达到3020万。 癌症负担的增加是由多种因素造成的，包括人口增长和老龄化，以及随着社会和经济发展，某些癌症病因的患病率发生变化。 例如，根据世界卫生组织 (WHO) 的数据，到 2021 年 9 月，大约三分之一的癌症死亡将与烟草使用、高体重指数、酒精使用以及水果和蔬菜摄入量低有关。，归因于缺乏身体活动。 因此，预计增加烟草消费会导致癌症患病率增加，从而促进市场增长。

此外，近期临床研究取得的良好结果也可能会在未来带来显着的市场增长。 例如，2021 年 2 月启动了一项名为“热休克蛋白 (HSP)70 以量化和表征晚期或转移性肿瘤患者的循环肿瘤细胞”的研究，以证明热休克蛋白 HSP70 在晚期或转移性肿瘤患者中循环据透露，它可以评估分离和量化肿瘤细胞 (CTC) 的能力。

因此，由于上述因素，研究涵盖的市场预计在研究期间将显着增长。 然而，与高诊断成本、缺乏认识和采用先进 CTC 技术的意愿低相关的检测和表征 CTC 的技术困难预计将进一步阻碍市场增长。

主要市场趋势

在循环肿瘤细胞（CTC）市场中，阴性富集部分有望占据主要市场份额

对于阳性富集方法，CTCs 由于其异质性而无法分离。 然而，在负富集方法中，血细胞的精确消耗允许分离外来和完整的 CTC。 由于这种负浓缩技术的优越性，预计未来会被采用。

此外，预计在不久的将来，各种类型癌症患病率的上升也将推动这一细分市场的增长。 根据国际癌症研究机构2020年的统计，肝癌是全球第6大常见癌症和第3大癌症死因，新发病例905,677例，估计死亡人数为830,180人。 东亚的发病率最高，为 491,687 例。 此外，北美的发病率为 46,599 人，西欧为 26,128 人。 总体而言，男性肝癌的发病率大约是女性的三倍。

此外，根据美国癌症协会 2022 年 1 月发表的一篇论文，肾癌是美国男性和女性最常见的 10 种癌症之一。 总体而言，患肾癌的终生风险相当高，男性约为 46 分之一，女性约为 80 分之一。 随着这种负担的增加，癌症预防已成为最重要的问题之一。 循环肿瘤细胞的分析对于监测疾病进展和对治疗的反应非常重要，特别是对于新型抗癌药物的伴随诊断和研究疾病进展的机制。

负富集在分离 CTC 方面也优于正富集，因此预计该部分在预测期内将呈现高增长。 例如，在 2021 年 10 月发表的一项题为“使用 3D 打印设备从未经处理的全血中负向富集循环肿瘤细胞”的研究中，负向富集方法导致了对 CTC 以及粘附免疫剂的无偏检测。它是据说是有利的，因为它可以生成不含 的完整肿瘤细胞，从而消除下游研究中的潜在伪影。 因此，由于负浓缩方法优于其他浓缩技术，预计该细分市场将显着增长。

因此，由于上述因素，市场细分预计将对市场增长做出重大贡献。

北美将占据很大的市场份额，预计在预测期内也会如此

由于癌症负担增加、产品批准和研发活动增加等因素，预计北美将对显着的市场增长做出贡献。 例如，据2022年美国癌症协会估计，2022年全国将诊断出约236,740例肺癌新病例。 根据同一数据，2022 年将报告 79,000 例肾癌新病例和 13,920 例肾癌死亡病例。 癌症的高负担预计将增加对 CTC 检测试剂盒的需求，从而推动市场增长。

此外，预计所研究市场的产品批准将进一步推动市场增长。 例如，2020 年 11 月，美国食品和药物管理局 (FDA) 扩大了一种被称为液体活检的血液检测的批准用途，以帮助医生为一些癌症患者选择最佳治疗方案。我做到了 该测试可识别释放到血液中的肿瘤细胞 DNA 中与癌症相关的遗传变化。

此外，根据 2020 年 2 月发表的“癌细胞改变蛋白质生产机制以加速转移”的研究，从乳腺癌患者血液中富集的 CTCs 具有高水平的核醣体蛋白 (RP)，它们的存在具有与疾病侵袭性增加和临床结果差有关。 因此，评估 CTC 中核醣体蛋白存在的研究将导致有效的癌症诊断，从而推动市场。 在美国还有 CellSearch 循环肿瘤细胞试剂盒，它是美国食品和药物管理局 (FDA) 批准的最成功的产品之一。 该产品通过多个州的各种公共和私人支付机构提供报销设施，包括 Cigna Government Services、Noridian 和 United Healthcare。 美国的几所大学依靠 CTC 应用来推进病理学和实验医学的实践。

因此，由于上述所有因素，预计该市场在预测期内将呈现高速增长。

竞争格局

由于大大小小的参与者的存在，市场得到了合理的整合。 一些市场参与者包括 Advanced Cell Diagnostics Inc.、Aviva Biosciences、Biocept Inc.、Creatv Micro Tech、LungLife AI Inc.、Menarini Silicon Biosystems、Miltenyi Biotec、Precision For Medicine（前身为 ApoCell）和 Qiagen NV。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 生物医学成像和生物工程技术的进步
    • 对预防医学和伴随诊断的需求不断增长
    • 癌症患病率增加
  • 市场製约因素
    • 与高诊断成本相关的 CTC 检测和表征技术困难
    • 缺乏认可，也不愿意采用先进的 CTC 技术
  • 波特的五力分析
    • 新人进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模 - 百万美元）

  • 按技术
    • CTC 富集方法
      • 积极充实
      • 负面充实
      • 其他技术
    • CTC检测方法
      • 免疫细胞化学法
      • 分子（RNA）基础技术
      • 其他 CTC 检测方法
  • 通过申请
    • 多体性
    • RNA 分析
    • 蛋白质表达
    • 细胞间通讯
    • 其他应用
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东和非洲地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Advanced Cell Diagnostics Inc.
    • Aviva Biosciences
    • Biocept Inc.
    • Creatv Micro Tech Inc.
    • LungLife AI Inc.
    • Menarini Silicon Biosystems
    • Miltenyi Biotec
    • Precision for Medicine（Formerly ApoCell）
    • Qiagen NV
    • BioChain Institute Inc.
    • Thermofisher
    • Sysmex Corporation

第七章市场机会与未来趋势

简介目录
Product Code: 60459

The circulating tumor cells (CTC) market is expected to register a CAGR of 9.5% during the forecast period (2022-2027).

The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. For instance, a study titled "Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study" in September 2020 reported that a total of 356 centers from 54 countries across six continents participated between April 21 and May 8, 2020. These centers serve 716,979 new patients with cancer every year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% reduced services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), staff shortage (17.98%), and restricted access to medications (9.83%). Thus, this indicates that due to COVID-19, there were disruptions in cancer care regarding reduced chemotherapy and radiotherapy services and ongoing research and development studies, thereby impacting the market growth.

Additionally, the study "Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer," published in September 2021, evaluated the effect of COVID-19-induced lockdown on newly diagnosed colorectal cancer cases through circulating tumor DNA and reported that tumor burden in patients who received a diagnosis after the lockdown was significantly higher compared with those who were diagnosed before the lockdown. This study indicated that the tumor burden increased during COVID-19 significantly and thus dramatically impacted the market growth.

The major factors for the growth of the circulating tumor cells (CTC) market include the advancements in biomedical imaging and bioengineering technology; the rising demand for preventive medicine and companion diagnostics; and the growing prevalence of cancer.

The global cancer burden is increasing; thus, cancer therapies must be modified according to regional and national priorities. For instance, according to the September 2021 update by the World Health Organization (WHO), cancer accounted for approximately 10 million worldwide deaths in 2020. The most common in 2020 (in terms of new cases of cancer) were: breast (2.26 million cases); lung (2.21 million cases); colon and rectum (1.93 million cases); prostate (1.41 million cases); skin (non-melanoma) (1.20 million cases); and stomach (1.09 million cases).

In addition, as per the 2020 statistics by Globocan, 19,292,789 people were diagnosed with cancer in 2020. As per the same source mentioned above, the number of people with cancer is estimated to reach 30.2 million by 2040. The increasing cancer burden is due to several factors, such as population growth and aging and the changing prevalence of specific causes of cancer linked to social and economic development. For instance, as per the World Health Organization (WHO), in September 2021, about one-third of deaths from cancer are due to tobacco use, high body mass index, alcohol use, low fruit and vegetable intake, and lack of physical activity. Thus, increasing tobacco consumption is expected to cause an increase in the prevalence of cancer, thereby contributing to market growth.

Moreover, the positive results from the recent clinical studies in the market may also boost and lead to significant market growth in the future. For instance, a study titled "Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells in Patients With Advanced or Metastatic Tumors" was initiated in February 2021 to evaluate the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors.

Thus, owing to the factors above, the studied market is expected to grow significantly during the study period. However, technical difficulties in the detection and characterization of CTCs associated with the high cost of diagnosis, lack of awareness, and unwillingness to adopt advanced CTC technologies are expected to hamper the market's growth further.

Key Market Trends

The Negative Enrichment Segment is Expected to Hold a Major Market Share in the Circulating Tumor Cells (CTC) Market

In the case of the positive enrichment method, it cannot isolate CTCs depending on heterogeneous properties. However, the negative enrichment method can isolate heterogeneous and intact CTCs by precisely eliminating blood cells. Thus, such an advantage of negative enrichment technology is expected to increase its adoption over the coming years.

Moreover, the rising prevalence of the various types of cancer is anticipated to bolster the segment's growth in the near future. According to the International Agency of Research on Cancer, 2020 Statistics, liver cancer was the sixth most common cancer and the third leading cause of cancer deaths worldwide, with an estimated 905,677 new cases and 830,180 deaths. East Asia had the highest incidence, with 491,687 cases. Moreover, the incidence rate was 46,599 in North America and 26,128 in western Europe. Overall, the incidence rate of liver cancer is approximately three times higher in males than in females.

Furthermore, according to an article published by the American Cancer Society in January 2022, kidney cancer is among the ten most common cancers in both men and women in United States. Overall, the lifetime risk for developing kidney cancer in men is about 1 in 46, and in women is about 1 in 80, which is significantly high. Cancer prevention is one of the most significant challenges with this growing burden. The analysis of circulating tumor cells is a substantial aspect of monitoring disease progression or response to treatment, specifically as a companion diagnostic for new anticancer drugs and research into the mechanisms of disease progression.

In addition, negative enrichment has advantages over positive enrichment in isolating CTCs, owing to which the segment is expected to witness high growth over the forecast period. For instance, the study titled "Negative enrichment of circulating tumor cells from unmanipulated whole blood with a 3D printed device," published in October 2021, stated that the negative enrichment approach is advantageous because it leads to the unbiased detection of CTCs and also produces intact tumor cells free of attached immuno-agents, eliminating potential artifacts in downstream studies. Thus, the market segment is expected to grow significantly with the advantages of negative enrichment methods over other enrichment technologies.

Thus, the studied segment is expected to contribute significantly to the market's growth owing to the abovementioned factors.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to contribute to the significant growth of the market owing to factors such as the increasing burden of cancer, product approvals, and rising research and development activities. For instance, according to the estimates of the 2022 American Cancer Society, Inc., about 236,740 new cases of lung cancer will be diagnosed in the country in 2022. The same source also states that 79,000 new cases of kidney cancer and 13,920 deaths will be reported in 2022 from kidney cancer. The high burden of cancer is expected to boost the demand for CTC detection kits, thereby driving market growth.

Additionally, product approvals in the studied market are further expected to drive market growth. For instance, in November 2020, the Food and Drug Administration (FDA) expanded the approved uses for a blood test, known as a liquid biopsy, that can help doctors pick the best treatments for some people with cancer. The test identifies cancer-related genetic changes in DNA from tumor cells released into the blood.

Moreover, according to a study, "Cancer cells alter protein production machinery to hasten metastasis," published in February 2020, CTCs enriched from the blood of breast cancer patients have higher levels of ribosomal proteins (RP), and their presence is associated with increased disease aggressiveness and poor clinical outcomes. Thus, studies evaluating the presence of ribosomal proteins in CTCs will lead to an effective cancer diagnosis, thus driving the market. In addition, United States has one of the most successful products, the CellSearch Circulating Tumor Cell Kit, which is approved by the US Food and Drug Administration (FDA). The product has reimbursement facilities through various public and private payers in several states, such as Cigna Government Services, Noridian, and United Healthcare. Several universities across United States have relied on CTCs applications to advance the practice of pathology and laboratory medicine.

Thus, the market studied is expected to witness high growth over the forecast period owing to all the factors above.

Competitive Landscape

The market studied is a moderately consolidated market, owing to the presence of small and large market players. Some market players are Advanced Cell Diagnostics Inc., Aviva Biosciences, Biocept Inc., Creatv Micro Tech, Inc., LungLife AI Inc., Menarini Silicon Biosystems, and Miltenyi Biotec, Precision For Medicine (Formerly ApoCell), and Qiagen NV.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Advancements in Biomedical Imaging and Bioengineering Technology
    • 4.2.2 Rising Demand for Preventive Medicine and Companion Diagnostics
    • 4.2.3 Increasing Prevalence of Cancer
  • 4.3 Market Restraints
    • 4.3.1 Technical Difficulties in Detection and Characterization of CTCs Associated with High Cost of Diagnosis
    • 4.3.2 Lack of Awarness and Unwillingness for the Adoption of Advanced CTC Technologies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Technology
    • 5.1.1 CTC Enrichment Methods
      • 5.1.1.1 Positive Enrichment
      • 5.1.1.2 Negative Enrichment
      • 5.1.1.3 Other Technologies
    • 5.1.2 CTC Detection Methods
      • 5.1.2.1 Immunocytochemical Technology
      • 5.1.2.2 Molecular (RNA)-based Technology
      • 5.1.2.3 Other CTC Detection Methods
  • 5.2 By Application
    • 5.2.1 Multiple Chromosome Abnormalities
    • 5.2.2 RNA Profiling
    • 5.2.3 Protein Expression
    • 5.2.4 Cellular Communication
    • 5.2.5 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Advanced Cell Diagnostics Inc.
    • 6.1.2 Aviva Biosciences
    • 6.1.3 Biocept Inc.
    • 6.1.4 Creatv Micro Tech Inc.
    • 6.1.5 LungLife AI Inc.
    • 6.1.6 Menarini Silicon Biosystems
    • 6.1.7 Miltenyi Biotec
    • 6.1.8 Precision for Medicine (Formerly ApoCell)
    • 6.1.9 Qiagen NV
    • 6.1.10 BioChain Institute Inc.
    • 6.1.11 Thermofisher
    • 6.1.12 Sysmex Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS